ASH 2017 | Novel PD-1 inhibitor and BTK inhibitor combination: tislelizumab and zanubrutinib
Constantine Tam
Phase I studies investigating a new monoclonal antibody that works through the inhibition of PD-1 have shown similar levels of efficacy and safety as the current PD-1 inhibitors pembrolizumab and nivolumab, as explained here by Constantine Tam, MD, FRACP, FRCPA, of the Peter MacCallum Cancer Centre, Melbourne, Australia. However, the main area of interest in this drug would be to see its efficacy when combined with a BTK inhibitor, which is currently happening in a Phase Ib study (NCT02795182). This interview was recorded at the American Society of Hematology (ASH) Annual Meeting 2017, held in Atlanta, GA.
Related videos
Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill
1:39
Venetoclax monotherapy in MCL: longer-term results
Matthew Davids
1:38
Ipilimumab, rather than nivolumab for relapsed heme malignancies post allo-SCT
Matthew Davids
2:40
Successful use of zanubrutinib for R/R MCL in China
Yuqin Song
4:27
CAR-T gives sustained disease control in R/R adult DLBCL: updated JULIET analysis
Richard Thomas Maziarz
